TORONTO, March 05, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that combines real-time Magnetic Resonance (“MR”) imaging and ultrasound technology for the precise, incision-free ablation of diseased tissue, announced today that management will present an update on the Company’s business at the Cowen and Company 39th Annual Health Care Conference on Wednesday, March 13, 2019 at 9:20 a.m. Eastern Time at the Boston Marriott Copley Place hotel.

The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investor Relations section.

About Profound Medical Corp.

Profound Medical develops and markets customizable therapies for incision- and radiation-free ablation of diseased tissue. 

Profound is commercializing TULSA-PRO^®, a novel technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop thermal feedback control. TULSA-PRO^® is designed to provide predictable and precise ablation of both cancerous and benign prostate tissue while protecting the surrounding anatomy to help preserve the prostate’s normal function. TULSA-PRO^® is CE marked and has been limitedly commercially launched in key European and other CE mark jurisdictions. TULSA-PRO^® is proving to be a flexible technology in the treatment of a variety of prostate diseases including localized intermediate stage cancer, urinary retention and hematuria in late stage cancer, localized radio-recurrent cancer, and large volume benign prostatic hyperplasia (BPH).

Profound has completed enrollment in a multicenter, prospective clinical trial, TACT, which, if successful, is expected to support its application to the FDA for approval to market TULSA-PRO^® in the United States

Profound is also commercializing Sonalleve^®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve^® has also been approved by the Chinese Food and Drug Administration for the non-invasive treatment of uterine fibroids. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve^® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

Forward-Looking Statements

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer, uterine fibroids and palliative pain treatment. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.  Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com 
T: 647.872.4849